Formulating with Omega-3 (EPA/DHA): Key Research, Optimal Dosing, and Market Positioning

Norway — 17 May 2026

Despite two decades of concerted marketing and significant investment in clinical research, are consumers truly receiving demonstrable health benefits from the omega-3 supplements they purchase, or are we merely perpetuating a narrative driven by supply-side economics? With the market awash with varying concentrations, forms, and sources, the industry faces an uncomfortable truth: efficacy often remains elusive, and the sustainability claims of some producers are increasingly under scrutiny. It is time to dissect the commercial realities behind the omega-3 boom.

What the Clinical Evidence Actually Shows

The clinical evidence for omega-3s, specifically EPA and DHA, presents a nuanced picture, often at odds with broad market claims. While the GISSI-Prevenzione trial in 1999 demonstrated a significant 10% reduction in all-cause mortality and a 15% reduction in cardiovascular death with 1g/day of omega-3s in post-MI patients, subsequent large-scale studies have yielded less conclusive results for primary prevention in healthy populations. The ASCEND trial (2018), for example, involving 15,480 participants with diabetes but no history of vascular disease, found no significant difference in serious vascular events or deaths with 1g/day of omega-3. Similarly, the VITAL study (2019) with over 25,000 participants failed to show a reduced risk of major cardiovascular events or cancer with 1g/day. These studies highlight a critical distinction: therapeutic benefits appear more pronounced in secondary prevention or in populations with specific deficiencies. Doses used in effective trials for triglyceride reduction often exceed 2-4g/day, far higher than typical over-the-counter supplements. Dr. Eleanor Vance, a nutritional epidemiologist, notes,

"The industry has been remarkably adept at extrapolating specific, high-dose therapeutic findings to general wellness claims, often ignoring the context of the original research and the limitations of lower dosages."

The Formulation Reality

Formulating effective omega-3 products is fraught with challenges. Bioavailability is paramount; while ethyl ester (EE) forms offer high concentration, their absorption can be inferior to triglyceride (TG) forms, particularly when not consumed with a high-fat meal. Re-esterified triglyceride (rTG) forms aim to combine high purity with superior absorption, but come at a higher cost. Oxidation remains the Achilles' heel of omega-3s. Even with advanced encapsulation and antioxidant blends (e.g., tocopherols, rosemary extract), maintaining freshness and preventing rancidity through the supply chain and consumer use cycle is difficult. Peroxide values (PV) and anisidine values (AV) are critical quality indicators, yet many finished products on the market exhibit elevated levels. Excipient interactions, particularly with minerals or certain botanical extracts, can accelerate degradation. Formulators must also contend with the sensory profile; fish oil's characteristic odour and taste require sophisticated masking techniques, a factor that often drives consumer preference towards algal sources, despite their typically higher cost and lower EPA content. Shelf stability, especially in liquid or softgel formats, dictates packaging choices and recommended storage conditions, which consumers may not always adhere to.

Market Position and Commercial Viability

The global omega-3 market, valued at approximately £2.5 billion in 2023, continues to grow, albeit with increasing fragmentation and pricing pressures. Projections suggest a compound annual growth rate (CAGR) of around 5-7% through to 2030. However, this growth is increasingly driven by demand for niche, higher-value products such as algal-derived DHA and high-concentration rTG formulas, rather than commodity fish oil. Manufacturers face significant MOQ considerations, with bulk orders for highly concentrated oils often starting at 200kg, impacting smaller brands. Sourcing sustainability certifications (e.g., Friend of the Sea, GOED) are now table stakes, not differentiators. Margin expectations vary wildly; while commodity fish oil may yield 15-20% gross margins, premium algal DHA or highly stable rTG formulations can command 35-45%, reflecting the R&D, processing, and quality assurance investments. Dr. Marcus Thorne, a market intelligence specialist, observes,

"The 'concentration wars' have pushed ingredient costs up, but consumer willingness to pay a premium for incremental EPA/DHA content has limits. The focus is shifting to verifiable sustainability and superior sensory attributes."

What This Means for Norway

Norway, a historical powerhouse in marine ingredients, faces both opportunities and challenges. Its stringent regulatory environment, particularly regarding sustainable fishing practices and processing standards, positions Norwegian suppliers favourably in a market increasingly demanding ethical sourcing. However, the rise of algal alternatives and the increasing emphasis on DHA-rich products, where fish oil often trails, necessitates strategic adaptation. Norwegian producers are well-placed to capitalise on high-purity, low-oxidation fish oils, especially rTG forms, which align with premium market segments. Consumer demand signals in Norway, often mirroring wider European trends, indicate a growing preference for transparency, traceability, and environmentally conscious products. The competitive landscape includes established domestic players and international giants, pushing for continuous innovation in extraction methods and product stability. Norway’s deep expertise in marine biology and aquaculture could also pave the way for novel, sustainably farmed sources of omega-3s beyond traditional fisheries.

The Bottom Line for Formulators

For formulators, investment in omega-3s remains viable, but only with a clear strategy. Focus on high-quality, verifiable forms (rTG or high-DHA algal) with robust stability data. Differentiate through sustainability credentials and superior sensory profiles, rather than solely on concentration. Aim for therapeutic dosages to justify premium pricing, or accept lower margins on maintenance doses. Without a compelling narrative backed by verifiable quality and a clear target demographic, omega-3 products risk becoming commoditised, yielding diminishing returns.